Mood Stabilizers

Overview

What "Mood Stabilizer" Means

The term mood stabilizer is clinical rather than strictly pharmacological. It generally refers to a medication that treats one pole of bipolar illness (mania or depression), prevents recurrence, and does not destabilize the opposite pole. Lithium is the prototypical agent. Anticonvulsants such as valproate, lamotrigine, and carbamazepine acquired this designation after their psychotropic effects emerged. Second-generation antipsychotics — quetiapine, olanzapine, aripiprazole, lurasidone, cariprazine, and others — now play a major role in bipolar care and are sometimes described as mood stabilizers in functional terms, though pharmacologically they are antipsychotics.

A Brief History

Lithium's mood-regulating effects were rediscovered in the 1940s by Australian psychiatrist John Cade and adopted into modern psychiatry over the following decades. Valproate was synthesized in the 19th century but introduced as an anticonvulsant in the 1960s, with antimanic activity confirmed later. Carbamazepine emerged for both epilepsy and bipolar disorder beginning in the 1970s. Lamotrigine, originally an anticonvulsant, was found in the 1990s to have specific benefits for the depressive pole and for maintenance of bipolar I disorder.

Why "Stabilizing" Matters

Bipolar disorder is a recurrent illness. Without effective long-term treatment, most patients experience repeated episodes of mania, hypomania, and depression — each carrying functional, occupational, and relational costs and, with each episode, potentially worsening course. Mood stabilizers aim not only to resolve acute episodes but to flatten the long-term trajectory of the illness, reducing the frequency and severity of recurrence.

How Mood Stabilizers Work

Lithium

Lithium is a simple monovalent cation, and despite over seven decades of clinical use its mechanism is still incompletely understood. Several plausible pathways have been identified. Lithium inhibits inositol monophosphatase, which depletes inositol and affects second-messenger signaling. It inhibits glycogen synthase kinase-3 (GSK-3), a regulator of neuronal plasticity and circadian function. It modulates monoaminergic neurotransmission, supports neurotrophic factors such as BDNF, and stabilizes circadian rhythms. Its therapeutic effect likely emerges from the convergence of these actions rather than from a single target.

Valproate

Valproate (valproic acid, divalproex sodium; Depakote and related formulations) enhances GABAergic inhibition, modulates sodium channel function, and inhibits histone deacetylase, which affects gene expression. Its antimanic effects develop rapidly relative to lithium, which makes it attractive for acute mania.

Lamotrigine

Lamotrigine (Lamictal) blocks voltage-sensitive sodium channels and modulates glutamate release. Its psychotropic profile is unusual: it has limited acute antimanic activity but strong evidence for preventing depressive episodes in bipolar I disorder. The slow titration required for safety also means it is not typically used for rapid mood stabilization.

Carbamazepine and Oxcarbazepine

Carbamazepine (Tegretol, Equetro) blocks voltage-gated sodium channels and influences several other neurotransmitter systems. It induces its own metabolism over time (auto-induction) and is a potent inducer of hepatic CYP enzymes, contributing to many drug interactions. Oxcarbazepine (Trileptal) is a related compound with a somewhat different metabolic profile and is sometimes used in bipolar disorder, although its evidence base is more limited.

Atypical Antipsychotics as Functional Mood Stabilizers

Many second-generation antipsychotics act on D2, 5-HT2A, and other receptor systems to produce antimanic and, for some agents (quetiapine, lurasidone, cariprazine, olanzapine-fluoxetine combination, lumateperone), antidepressant effects in bipolar disorder. Their place in modern bipolar care is substantial; they are often combined with lithium or valproate for greater efficacy.

Major Medications in This Class

Lithium

Available as lithium carbonate (immediate-release and extended-release) and lithium citrate. It is renally excreted, with steady-state blood levels typically targeted between 0.6 and 1.2 mEq/L depending on phase of illness. Brand names include Eskalith and Lithobid; generic formulations are widely used.

Valproate (Divalproex, Valproic Acid)

Available as valproic acid, divalproex sodium (Depakote, Depakote ER), and intravenous formulations. Therapeutic blood levels are typically targeted around 50–125 mcg/mL in acute mania. Onset of effect is faster than lithium, often within several days.

Lamotrigine

Available as immediate-release and extended-release (Lamictal, Lamictal XR). Titration over 5–6 weeks is essential to reduce the risk of serious rash. Dose adjustments are required when used with valproate (which significantly raises lamotrigine levels) or with strong CYP inducers (which lower them).

Carbamazepine

Available in immediate-release and extended-release forms (Tegretol, Tegretol XR, Equetro, Carbatrol). The extended-release form Equetro is FDA-approved for acute bipolar mania. Auto-induction of metabolism means doses may need to increase after the first weeks of treatment to maintain levels.

Oxcarbazepine

Oxcarbazepine (Trileptal) is structurally related to carbamazepine, with fewer drug interactions and no auto-induction. Evidence in bipolar disorder is more limited, and it is generally not first-line.

Other Agents Sometimes Discussed

Topiramate, gabapentin, and pregabalin have all been studied in mood disorders. Topiramate (Topamax) has not shown reliable mood-stabilizing efficacy in controlled trials but is sometimes used for weight effects, alcohol use disorder, and migraine prevention. Gabapentin and pregabalin have anxiolytic uses but are not effective as primary mood stabilizers.

FDA-Approved and Off-Label Uses

Bipolar I Disorder

• Acute mania: Lithium, valproate, and carbamazepine extended-release are FDA-approved. Several atypical antipsychotics are also approved and are often used alone or in combination.
• Acute bipolar depression: Lamotrigine is sometimes used, although its main evidence is for maintenance rather than acute episodes. Quetiapine, lurasidone, cariprazine, lumateperone, and the olanzapine-fluoxetine combination have FDA approval for bipolar depression.
• Maintenance treatment: Lithium and lamotrigine are core agents. Valproate, certain atypical antipsychotics, and combination regimens are also used.

Bipolar II Disorder

Although evidence is more limited than for bipolar I, lithium, lamotrigine, and quetiapine are commonly used. Antidepressant use in bipolar II is more cautiously approached because of risk of switching, mood destabilization, or accelerated cycling.

Other Psychiatric Uses

• Augmentation in treatment-resistant unipolar depression (lithium has the strongest evidence)
• Schizoaffective disorder, often in combination with antipsychotics
• Cyclothymic disorder, in selected cases
• Aggression and impulsivity, in some contexts

Neurological Uses

Valproate, lamotrigine, and carbamazepine retain primary roles in epilepsy. Carbamazepine and oxcarbazepine are also used for trigeminal neuralgia and certain neuropathic pain syndromes. Lamotrigine is used in some seizure disorders.

Common and Serious Side Effects

Lithium

• Common: Fine tremor, increased thirst and urination (often from nephrogenic diabetes insipidus), nausea, diarrhea, weight gain, acne, hair thinning.
• Thyroid: Hypothyroidism (more common than hyperthyroidism) — sometimes requiring thyroid hormone replacement.
• Renal: Reduced urinary concentrating ability. Long-term, a minority of patients develop chronic kidney disease, particularly with episodes of toxicity or extended high-level exposure.
• Cardiac: Benign T-wave changes are common. Rarely, sinus node dysfunction occurs.
• Lithium toxicity: A medical emergency. Early signs include coarse tremor, ataxia, confusion, slurred speech, vomiting, and diarrhea. Severe toxicity progresses to seizures, coma, and death. Risk factors include dehydration, sodium depletion, NSAID or ACE inhibitor use, and renal impairment.

Valproate

• Common: Nausea, sedation, weight gain, hair thinning, tremor, increased appetite.
• Hepatic: Liver enzyme elevation; rare but potentially fatal hepatotoxicity, particularly in children under 2 and in mitochondrial disorders.
• Pancreatic: Rare acute pancreatitis.
• Hematologic: Thrombocytopenia.
• Endocrine and reproductive: Polycystic ovary syndrome features in some women, hyperammonemia, insulin resistance.
• Teratogenicity: A 6–10% rate of major congenital malformations including neural tube defects, plus reduced IQ and increased autism risk with prenatal exposure. This is the most severe teratogenic profile of any psychotropic in common use.

Lamotrigine

• Common: Headache, dizziness, mild rash, nausea, blurred vision.
• Serious rash: Stevens-Johnson syndrome and toxic epidermal necrolysis are rare but life-threatening. Risk is markedly increased by rapid titration and by concurrent valproate. Any rash during lamotrigine titration is treated as a potential emergency.
• Rare: Aseptic meningitis, hemophagocytic lymphohistiocytosis (HLH).

Carbamazepine

• Common: Sedation, dizziness, blurred vision, ataxia, nausea.
• Hematologic: Mild leukopenia is common; rare but serious agranulocytosis and aplastic anemia occur.
• Hyponatremia: Through SIADH-like effect, especially in older adults.
• Hepatic: Enzyme elevation; rare hepatotoxicity.
• Skin: Stevens-Johnson syndrome, particularly elevated in individuals of Asian ancestry with HLA-B*1502 allele; genetic screening is recommended before initiation in at-risk populations.
• Teratogenicity: Increased risk of neural tube defects and other malformations.

Drug Interactions and Warnings

Lithium

• NSAIDs (e.g., ibuprofen, naproxen) raise lithium levels and increase toxicity risk.
• ACE inhibitors and angiotensin receptor blockers raise lithium levels.
• Thiazide diuretics raise lithium levels significantly.
• Loop diuretics also raise levels, generally less than thiazides.
• Caffeine increases renal excretion; sudden reduction in caffeine intake can raise levels.
• Dehydration, low-sodium diet, vomiting, and diarrhea all raise toxicity risk.

Valproate

• Valproate strongly raises lamotrigine levels — lamotrigine dosing must be adjusted when added.
• Valproate raises levels of phenobarbital and certain other anticonvulsants.
• Carbapenem antibiotics dramatically lower valproate levels.

Lamotrigine

• Strong CYP inducers (carbamazepine, phenytoin, rifampin) lower lamotrigine levels.
• Estrogen-containing oral contraceptives lower lamotrigine levels; placebo week may produce a spike.
• Valproate raises lamotrigine levels and rash risk.

Carbamazepine

• A potent inducer of CYP3A4 and other enzymes; lowers levels of many medications including oral contraceptives, certain anticoagulants, antiretrovirals, immunosuppressants, and many psychotropics.
• Affected drugs may lose efficacy. Carbamazepine itself also induces its own metabolism (auto-induction).

Important Warnings

All four core mood stabilizers have meaningful risks in pregnancy. Valproate and carbamazepine are particularly teratogenic. Lithium has an elevated risk of Ebstein's cardiac anomaly (although the absolute risk is lower than once believed). Lamotrigine is generally considered the most favorable of the four for pregnancy but is not entirely without concern. Reproductive planning should involve a knowledgeable clinician.

Starting, Monitoring, and Stopping

Baseline Assessment

Before starting a mood stabilizer, baseline assessments commonly include:

• Comprehensive metabolic panel (kidney and liver function, electrolytes)
• Thyroid function tests
• Complete blood count
• Pregnancy test where applicable
• Electrocardiogram in older patients or those with cardiac risk
• For carbamazepine: HLA-B*1502 in genetically at-risk groups

Therapeutic Drug Monitoring

Lithium, valproate, and carbamazepine all require periodic blood level monitoring. Lithium levels are typically drawn 12 hours after the last dose. Frequency of monitoring varies — more often at initiation, dose changes, or with illness — and reduces as treatment stabilizes. Lamotrigine does not require routine level monitoring.

Onset and Duration

Valproate often produces noticeable antimanic effects within days. Lithium may show benefit in 1–2 weeks for acute mania, with maintenance effects fully emerging over months. Lamotrigine takes weeks to titrate to therapeutic dose and longer for full maintenance effect. Bipolar disorder is generally a long-term condition; mood stabilizers are typically used for sustained periods, with continuation decisions based on history, response, and tolerability.

Stopping

Abrupt lithium discontinuation has been associated with rapid relapse and possible reduced future response to lithium. Tapering over weeks to months is generally preferred. Valproate, carbamazepine, and lamotrigine should be tapered both for mood and seizure-risk reasons. Discontinuation is generally a clinical decision made jointly between patient and prescriber.

Special Populations

Pregnancy and Postpartum

Bipolar disorder is highly sensitive to the perinatal period; relapse risk is high if treatment is stopped during pregnancy. Decisions about mood stabilizers in pregnancy are individualized and complex. Valproate is generally avoided unless no acceptable alternative exists. Carbamazepine carries similar but somewhat lower teratogenic risk. Lithium can be used with monitoring; the absolute cardiac malformation risk is small but real. Lamotrigine has the most favorable reproductive safety profile among the core mood stabilizers but still requires careful management because of changes in metabolism during pregnancy. The postpartum period is associated with particularly high relapse risk.

Elderly Patients

Older adults are more sensitive to lithium and develop toxicity at lower blood levels. Renal function declines with age, narrowing the therapeutic window. Carbamazepine commonly causes hyponatremia in older patients. Drug-drug interactions become more relevant as comorbidities and polypharmacy increase.

Children and Adolescents

Mood stabilizer use in pediatric bipolar disorder has expanded, although it remains complex and somewhat controversial in early childhood. Lithium has FDA approval in adolescents for bipolar disorder. Lamotrigine and other agents are used in selected cases. Diagnosis of bipolar disorder in young children should be made with care, as many presentations overlap with ADHD, anxiety, trauma, and disruptive mood dysregulation disorder.

Comorbid Medical Conditions

Renal disease alters lithium dosing. Hepatic disease alters dosing of valproate and carbamazepine. Cardiac disease and electrolyte disturbances modify risk profiles. Patients with migraine, epilepsy, or chronic pain may benefit from agents that overlap therapeutically. Comprehensive medical evaluation supports individualized choice.

Controversies and Modern Practice

Lithium's Underuse

Despite its strong evidence base — including unique data on suicide reduction — lithium has seen declining prescribing in several countries over recent decades. Reasons include the burden of blood monitoring, side-effect concerns, perceived complexity, and the marketing emphasis on newer agents. Advocates argue that earlier and more consistent use of lithium would meaningfully improve outcomes in bipolar disorder.

Valproate in Reproductive-Age Patients

Recognition of valproate's profound teratogenicity has led to substantial regulatory action in Europe and elsewhere, with strong recommendations against use in girls and women of reproductive potential unless other treatments have failed and reliable contraception is in place. Clinical practice continues to evolve toward more conservative use in this population.

Mood Stabilizers Versus Antipsychotics

The growing use of atypical antipsychotics in bipolar disorder raises questions about the optimal combinations and sequencing of treatment. Combination therapy (e.g., lithium plus an atypical antipsychotic) often outperforms monotherapy but at the cost of additional side effects. Choice depends on illness phase, predominant polarity, prior response, and tolerability.

Antidepressant Use

Whether to add antidepressants in bipolar depression — and which ones — has been long debated. Concerns include induction of mania, hypomania, mixed states, or rapid cycling. Most guidelines reserve antidepressants for bipolar depression as adjuncts to a mood stabilizer or atypical antipsychotic, not as monotherapy.

The "Mood Stabilizer" Concept Itself

Some clinicians and researchers have argued that the term mood stabilizer is too broad and inconsistently used, potentially obscuring meaningful differences among agents. Others find the concept clinically useful as long as the limits of any single label are understood. Either way, individualized decision-making remains central.

What Patients Should Know

Adherence and Long-Term Care

Bipolar disorder is generally a chronic, recurrent illness, and consistent treatment substantially reduces relapse. Stopping medication when feeling well is a leading cause of recurrence. Building a sustainable medication routine — including pill reminders, blood-test scheduling, and communication with the prescriber — supports long-term stability.

Monitoring Side Effects

Reporting tremor, excessive thirst, cognitive dulling, weight changes, sedation, rash, or new movements helps the prescriber adjust treatment. Symptoms that should prompt urgent attention include a new rash (especially on lamotrigine), signs of lithium toxicity (coarse tremor, ataxia, confusion, vomiting), and severe abdominal pain (valproate-related pancreatitis is rare but serious).

Pregnancy Planning

For people who can become pregnant, mood stabilizer choices have lifelong implications for reproductive planning. Conversations about contraception, folic acid supplementation, pre-pregnancy regimen review, and perinatal psychiatric care are important parts of treatment.

Lifestyle and Self-Management

Regular sleep, limited alcohol use, stress management, social rhythm therapy, and recognition of early warning signs of mood episodes are evidence-based supports for medication. Many patients find psychoeducation, cognitive behavioral therapy, family-focused therapy, or interpersonal and social rhythm therapy valuable alongside medication.

Working With Your Team

Mood stabilizer management often involves a psychiatrist, primary care physician, sometimes a therapist, and a pharmacist. Open communication across the team — particularly about new medications added for other conditions — reduces interaction-related risks.